Wednesday November 20, 2019

WHO Plans To Enhance It’s Combat Against Snakebites

WHO estimates venomous snakes bite 1.8 million to 2.7 million people a year

0
//
A snake charmer points out a snakebite during a performance with a snake outside a temple in Allahabad, India.
A snake charmer points out a snakebite during a performance with a snake outside a temple in Allahabad, India. VOA

Governments around the world plan to strike back harder against snakebite, a scourge that kills tens of thousands of people a year.

A World Health Organization (WHO) resolution raises the priority of improving snakebite prevention as well as access to effective and affordable anti-venom. The measure was approved by 192 countries in late May.

The WHO estimates that venomous snakes bite 1.8 million to 2.7 million people a year, killing between 81,000 and 138,000 of them.

“For every person who dies following a snakebite, another four or five are left with disabilities such as blindness, restricted mobility or amputation, and post-traumatic stress disorder,” the WHO reports.

Snakebite envenoming is most prevalent in sub-Saharan Africa, South Asia and Southeast Asia, the WHO reports. People in rural, impoverished areas there and elsewhere are most at risk, challenged by poor or remote health systems, and limited diagnoses, ambulances and other emergency care – including reliable anti-venom.

Grass snake
Grass snake, Flickr

In sub-Saharan Africa, just 2 percent of people bitten by venomous snakes have access to appropriate anti-venom, says Medecins Sans Frontieres (MSF), the aid group also known as Doctors Without Borders.

“We need to know better the data [on] where most cases take place,” said Julien Potet, MSF’s policy adviser on neglected tropical diseases, speaking by phone last week from Geneva. “We need to better regulate the quality of the anti-venoms, to distribute them accordingly in the areas of highest need” and to make them affordable, “because otherwise they [patients] will not be able to access the product.”

Potet pointed out that French pharmaceutical company Sanofi Pasteur has stopped manufacturing Fav-Afrique, the only serum known to effectively treat bites from some sub-Saharan African snakes. The last batches of the company’s serum expired in June 2016.

Production of the anti-venom takes roughly two years, the in-Pharma Technologist website reported. It said the pharmaceutical company cited manufacturing costs, and competition from cheaper but less effective treatments, in its decision to stop producing Fav-Afrique.

MSF has estimated that the anti-venom costs a patient $250 to $500 for treatment.

Sanofi Pasteur announced in January that it had agreed to divest its anti-venom immunoglobulin range, which includes Fav-Afrique, to the U.K.-based firm MicroPharm.

“We hope this resolution will trigger some actions to better regulate the market … and to prioritize and subsidize” anti-venom production and distribution, Potet said.

“Now we need to make sure this resolution is translated into a concrete, fully funded action plan,” he added.

A researcher demonstrates how to extract venom from a snake to vacationing school children during a presentation at the Butantan Institute in Sao Paulo, Brazil, Jan. 23, 2015
A researcher demonstrates how to extract venom from a snake to vacationing school children during a presentation at the Butantan Institute in Sao Paulo, Brazil, Jan. 23, 2015, VOA

A WHO working group is expected to offer recommendations on how governments can bolster data collection, training for health workers, access to care and support for effective anti-venoms, according to Devex, a website aimed at the global development community. It said the group’s report is expected by Nov. 30.

Also read: Australian snakes have Asian origins study

Devex also reported that David Williams, the group’s chair, estimated “about $6 million was needed in 2018-2019 to prepare the recommendations, improve surveillance, deliver antivenoms, and address other technical and medical challenges.” (VOA)

Next Story

WHO Demands Strict Regulations on Vaping Products

WHO says there should be a ban on the promotion of electronic nicotine delivery systems to nonsmokers, pregnant women and youth

0
WHO
The World Health Organization also known as WHO says it is disturbed that vaping devices continue to be marketed as products that are healthy and that can wean smokers off their nicotine addiction. Wikimedia Commons

The World Health Organization also called WHO is calling for stricter regulations on the marketing and sale of e-cigarettes as more information comes to light about the potentially harmful impact of these products.

Health officials are increasingly worried about the risks posed by e-cigarettes as reported cases of deaths and illnesses from these devices spread from the United States to Europe and beyond. They see the recent death of a young man in Belgium and reports of vaping-related illnesses in the Philippines and other countries in the world as a call to action.

The World Health Organization says it is disturbed that vaping devices continue to be marketed as products that are healthy and that can wean smokers off their nicotine addiction.  WHO spokesman Christian Lindmeier tells VOA these industry health claims are unproven.

“While these electronic nicotine delivery systems may be less toxic than conventional cigarettes, this does not make them harmless,” he said.  “They produce aerosols from the vapor that contain toxicants that can result in a range of significant pathological changes.  These ends pose health risks for nonsmokers, to minors, to pregnant women — all of those who should not use such systems.”

The U.S. Centers for Disease Control and Prevention has confirmed at least 42 deaths in 24 states and the District of Columbia, and more than 2,100 illnesses related to vaping products.

WHO
The World Health Organization also called WHO is calling for stricter regulations on the marketing and sale of e-cigarettes as more information comes to light about the potentially harmful impact of these products. Pixabay

Vaping is an extremely profitable growth industry.  The number of people using vaping devices has increased from 7 million in 2011 to 41 million in 2018.  Profits have nearly tripled, from $6.9 billion five years ago to more than $19 billion today.  Getting the tobacco industry to refrain from the sale of electronic smoking devices will be extremely difficult.

The World Health Organization says long-term studies of health implications of electronic nicotine devices should begin.  In the meantime, the U.N. health agency is issuing recommendations that in some ways mirror those enacted to control tobacco use.

ALSO READ: Smart Bulbs Can Steal Personal Information Through Hacking

WHO says there should be a ban on the promotion of electronic nicotine delivery systems to nonsmokers, pregnant women and youth; measures should be taken to minimize the potential risks to users and others from these devices, and the tobacco industry should be prohibited from using unproven health claims to market vaping products.  (VOA)